167 related articles for article (PubMed ID: 26428728)
1. Adalimumab for refractory pulmonary sarcoidosis.
Minnis PA; Poland M; Keane MP; Donnelly SC
Ir J Med Sci; 2016 Nov; 185(4):969-971. PubMed ID: 26428728
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-α Inhibitor.
Au S; Mirsaeidi M; Aronson IK; Sweiss NJ
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):249-51. PubMed ID: 25363227
[TBL] [Abstract][Full Text] [Related]
3. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
Sweiss NJ; Noth I; Mirsaeidi M; Zhang W; Naureckas ET; Hogarth DK; Strek M; Caligiuri P; Machado RF; Niewold TB; Garcia JG; Pangan AL; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Apr; 31(1):46-54. PubMed ID: 24751453
[TBL] [Abstract][Full Text] [Related]
4. [Successful treatment with infliximab of a patient with refractory sarcoidosis].
Fouchier SM; Möller GM; Van Santen-Hoeufft M; Faber CG; Smeenk FW; Drent M
Ned Tijdschr Geneeskd; 2004 Dec; 148(49):2446-50. PubMed ID: 15626311
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept.
Jung JH; Kim JH; Song GG
Z Rheumatol; 2017 May; 76(4):372-374. PubMed ID: 28124746
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis.
Kamphuis LS; Lam-Tse WK; Dik WA; van Daele PL; van Biezen P; Kwekkeboom DJ; Kuijpers RW; Hooijkaas H; van Laar JA; Bastiaans J; Baarsma GS; van Hagen PM
Am J Respir Crit Care Med; 2011 Nov; 184(10):1214-6. PubMed ID: 22086995
[No Abstract] [Full Text] [Related]
8. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
Maloney NJ; Hisaw LD; Worswick S
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
[TBL] [Abstract][Full Text] [Related]
9. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.
Milman N; Graudal N; Loft A; Mortensen J; Larsen J; Baslund B
Clin Respir J; 2012 Oct; 6(4):238-47. PubMed ID: 22128762
[TBL] [Abstract][Full Text] [Related]
10. [TNFα blocking agents and sarcoidosis: an update].
Toussirot E; Pertuiset E
Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
[TBL] [Abstract][Full Text] [Related]
11. TNF-α: a treatment target or cause of sarcoidosis?
Amber KT; Bloom R; Mrowietz U; Hertl M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2104-11. PubMed ID: 26419478
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal therapy of sarcoidosis.
Korsten P; Mirsaeidi M; Sweiss NJ
Curr Opin Pulm Med; 2013 Sep; 19(5):516-23. PubMed ID: 23884295
[TBL] [Abstract][Full Text] [Related]
13. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Russell E; Luk F; Manocha S; Ho T; O'Connor C; Hussain H
Semin Arthritis Rheum; 2013 Aug; 43(1):119-24. PubMed ID: 23332903
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
Crommelin HA; van der Burg LM; Vorselaars AD; Drent M; van Moorsel CH; Rijkers GT; Deneer VH; Grutters JC
Respir Med; 2016 Jun; 115():72-7. PubMed ID: 27215507
[TBL] [Abstract][Full Text] [Related]
15. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches.
Baughman RP; Grutters JC
Lancet Respir Med; 2015 Oct; 3(10):813-22. PubMed ID: 26204816
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-α inhibitor use for treatment of refractory cardiac sarcoidosis in a patient with left ventricular assist device: Adalimumab use in refractory sarcoidosis in a patient with left ventricular assist device.
Krishnan M; Cupps TR; Sheikh FH
J Heart Lung Transplant; 2020 Dec; 39(12):1504-1505. PubMed ID: 32830024
[No Abstract] [Full Text] [Related]
17. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF therapeutics for the treatment of sarcoidosis.
Crommelin HA; Vorselaars AD; van Moorsel CH; Korenromp IH; Deneer VH; Grutters JC
Immunotherapy; 2014; 6(10):1127-43. PubMed ID: 25428650
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary sarcoidosis and latent tuberculosis in a patient with psoriasis treated with adalimumab.
Korta DZ; Ochieng P; Fishman D; Katz SE
Dermatol Online J; 2015 Jan; 21(1):. PubMed ID: 25612132
[TBL] [Abstract][Full Text] [Related]
20. Is there evidence for anti-TNF drugs in joint involvement in sarcoidosis?
Crommelin HA; Vorselaars AD; van Moorsel CH; Korenromp IH; Deneer VH; Grutters JC
Immunotherapy; 2015; 7(6):601. PubMed ID: 26098292
[No Abstract] [Full Text] [Related]
[Next] [New Search]
